Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03581006
Other study ID # 17-00127
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 12, 2018
Est. completion date March 4, 2021

Study information

Verified date December 2021
Source NYU Langone Health
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

This is a randomized-controlled unblinded clinical trial to investigate dietary intervention on metabolic biomarker assessment in World Trade Center (WTC) Lung Injury (LI) in firefighters. The purpose of this study is to evaluate biomarkers of metabolic dysregulation that have previously been found to predict WTC-LI in a case cohort study selected from the entire exposed firefighter cohort, and attempt to alter these metabolites using dietary intervention and a technology-supported behavioral modification program. Investigators will measure Pre/Post global metabolic expression in WTC-exposed, symptomatic firefighter serum sampled after 6-month intervention, as well as clinical outcomes of WTC-LI in the study group vs controls.


Description:

Investigators propose to measure metabolites on this expanded cohort with serum sampled before and after 6-month intervention with calorie restricted Mediterranean diet to: 1) determine the effects of a technology assisted calorie restricted diet on metabolic risk and lung function; 2) determine differences between usual care and intervention group using genomics and metabolomics that may be targetable markers for further evaluation; 3) quantify the metabolome and evaluate pre/post changes in BMI, FEV1, FeNo, vascular stiffness, and overall quality of life; and 4) explore dietary modification as treatment of WTC-LI. The biomarker profile of the cohort control will be useful for discovering biomarker associations with other disease manifestations such as: bronchial wall thickening on CT, obstruction on FEV1 /FVC ratio, bronchodilator response, methacholine reactivity, and other definitions of loss of FEV 1 . This cohort control will be an asset to future studies.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date March 4, 2021
Est. primary completion date March 4, 2021
Accepts healthy volunteers No
Gender Male
Age group 21 Years to 90 Years
Eligibility Inclusion Criteria: 1. Age 21-90. 2. Born male sex and currently identify as genetic male 3. FDNY rescue and recovery worker. 4. Documented WTC exposure. 5. Enrolled in the FDNY WTC Health Program 6. Subjects are willing and able to consent for themselves to study enrollment 7. Subjects are willing and able to participate in study procedures 8. Are able to perform their activities of daily living independently 9. Are either light duty or retired FDNY Firefighters 10. Have an FEV1 less than the LLN of predicted for age/sex/weight documented at any time after 9/11/2001. 11. Have a BMI>27 kg/m2 and <50kg/m2 12. Willing and able to modify their diet and activity level. 13. Subjects who have a spirometry available within the last 36 months, and at their post-9/11 visits at the FDNY 14. Demonstrate minimal proficiency using a smart phone 15. Have means to accommodate transportation to/from in-person visits Exclusion Criteria: 1. Have pre-existing and documented conditions or concurrent diagnoses, including (and not necessarily limited to) active cancer, severe heart disease, significant cognitive impairment, eating disorders, significant psychiatric illness, end-stage COPD, severe pulmonary hypertension, or organ transplant. 2. Concomitant use of interfering medication(s) or devices currently or within the month prior to enrollment, including anti-retrovirals, human monoclonal antibodies, supplemental daytime oxygen, and insulin pumps. 3. Severe gastrointestinal issues or illnesses that would prevent adherence to the proposed diets. 4. Severe kidney disease requiring dialysis 5. Severe liver disease requiring frequent medical intervention 6. Participating in other diet modification studies. 7. High dose steroid (>20mg prednisone or equivalent) or other hormonal treatments/chemotherapy use in the last month, including testosterone supplementation. 8. Life-expectancy < 6 months 9. BMI =50 kg/m2 or =27 kg/m2 10. Recent significant intentional or unintentional weight loss, defined as over 5% reduction in total body weight over the last month. (Blackburn Criteria). 11. Significant or severe alcohol abuse disorder

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Low-Calorie Mediterranean Diet
Participants in the intervention group will receive 6 months of education and behavioral counseling with self-monitoring to help them adopt a Mediterranean-style, calorie-restricted diet, and engage in physical activity
Combination Product:
Technology based monitoring and behavioral participation
Intervention participants will use smart phones to connect to intervention applications, WebEx, MyNetDiary
Other:
Usual care group
Control group, who will receive no dietary or behavioral intervention during the trial

Locations

Country Name City State
United States New York University School of Medicine New York New York

Sponsors (1)

Lead Sponsor Collaborator
NYU Langone Health

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Body mass index (BMI) Body mass (weight in kg) divided by square of the body height (measured in meters), expressed in units kg/m^2 4 Years
Secondary Pulmonary Function using FEV Measure Forced expiratory volume (FEV) using spirometer that measures the amount (volume) and/or speed (flow) of air that can be inhaled and exhaled. 4 Years
Secondary St. George's Respiratory Questionnaire (SGRQ) Airways-disease specific paper questionnaire assessing symptoms, effect on activity level, and impact on quality of life. 4 Years
Secondary Electrocardiogram (EKG) Non-invasive brief electrical recording of heart rate and rhythm using electrodes placed on the chest 4 years
Secondary Fraction of exhaled nitrous oxide (FENO) Simple breathing test to measure airway inflammation as often seen in asthma or particulate matter lung injury, measured in ppb. 4 years
Secondary Pulse Wave Velocity (PWV) Non-invasive measurement to ascertain vascular stiffness, by measuring the velocity at which the blood pressure pulse propogates through the circulatory system. This is done using a simple non-invasive blood pressure cuff assessment at the carotid and femoral arteries. It is measured as a velocity, in meters/per second. 4 years
Secondary Individual microbiome profile - stool sample Simple home collection of a stool sample using a sterile collection kit, provided to the human subject. Stool will be used to generate a microbiome profile unique to that individual, reported as bacterial species found in the gut flora, that may predict lung injury. There is no risk to the human subject aside that of providing a stool sample. All individual information is de-identified for personal protection. 4 years
Secondary 6-minute walk test (6MWT) Simple exercise capacity assessment measuring distance walked over 6 minutes, measured in meters. 4 years
Secondary Individual metabolomic profile - blood sample Routine blood testing via sterile phlebotomy to assess metabolic biomarkers that may or may not predict lung injury. These metabolites are generated in all individuals based on their dietary and exercise habits, underlying comorbidities, and unique metabolism. Measured in routine blood samples, and quantified based on unique chemical composition of that molecule. There is no additional risk to the human subject aside that of venipuncture. 4 years
Secondary Individual genomic profile - saliva sample Simple home collection of sputum/saliva sample using a buccal swab kit, provided to the human subject. Saliva will be used to generate a genetic profile unique to that individual, reported as chromosomes, genes, and proteins that may predict lung injury. There is no risk to the human subject aside that of providing a sputum sample. All individual information is de-identified for personal protection. 4 years
Secondary Short-form-36 (SF-36) questionnaire Generalized paper questionnaire for self-assessment of mental health, general health perception, and overall quality of life 4 years
Secondary Routine vital signs - Heart Rate Brief assessment of heart rate (pulse) measured in beats/per minute 4 years
Secondary Routine vital signs - Blood Pressure Subjects who have spirometry available within the last 36 months, and at their post-9/11 visits at the FDNY. 4 years
Secondary Routine vital signs - Body temperature Brief assessment of body temperature using a basic thermometer under the tongue, measured in degrees Fahrenheit 4 years
Secondary Neck circumference Assessment of neck circumference using basic measuring tape, recorded in centimeters 4 years
Secondary Waist circumference Assessment of waist circumference using basic measuring tape, recorded in centimeters 4 years
Secondary Bioelectrical impedance analysis (BIA) Assessment of lean body mass and total body fat percentage using an InBody bioelectrical impedance analysis scale. 4 years
Secondary Food Frequency Questionnaire Paper assessment of typical dietary intake over previous one month, multiple choice answers 4 years
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05054270 - Efficacy of Lung Ultrasound in Monitoring Fluid Resuscitation in Chest Trauma Patients
Not yet recruiting NCT04470297 - Melatonin Agonist on Hospitalized Patients With Confirmed or Suspected COVID-19 Phase 2
Not yet recruiting NCT01184313 - Acute Lung Injury After Aortic Valve Surgery N/A
Not yet recruiting NCT06296173 - Open Lung Protective Extubation Following General Anesthesia N/A
Not yet recruiting NCT03661502 - Effect of Variable Volume Ventilation on Lung Compliance N/A
Recruiting NCT04296071 - Neutrophil Phenotypic Profiling and Acute Lung Injury in Patients After Cardiopulmonary Bypass (CPB)
Completed NCT04645316 - The Effect of Sevoflurane and Desflurane on Clara Cell Protein on the Lung N/A
Recruiting NCT02299921 - Effect of Alcohol and Drugs of Abuse on Immune Function in Critically Ill Patients With Respiratory Failure
Recruiting NCT05559970 - Inhalational Sedation and Mechanical Power N/A
Recruiting NCT05228717 - Point-of-care Lung Ultrasound (POCUS)-Integrated Study of Admitted Patients With COVID-19
Recruiting NCT04372953 - Positive End-Expiratory Pressure (PEEP) Levels During Resuscitation of Preterm Infants at Birth (The POLAR Trial). N/A
Not yet recruiting NCT05363085 - The Cerebral-Respiratory Interaction in Controlled Mechanically Ventilated Neurosurgical Patients. (The CeRes-CMV Study)
Recruiting NCT02444858 - Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Paraquat Poisoning Induced Lung Injury Phase 1/Phase 2
Completed NCT03924206 - Hazardous Surgical Smoke: Risk Assessment and Evaluation of a New Smoke Extractor System in the Surgical Unit
Withdrawn NCT01939067 - Infant Pulmonary Mechanics: High Flow Nasal Cannula Versus Nasal CPAP Phase 1
Recruiting NCT05401474 - Individualization Flow in Patients Treated With High Flow Nasal Therapy (iFLOW) N/A
Completed NCT03437499 - Adrenomedullin Changes After Sustained Inflation or Positive Pressure Ventilation at Birth N/A
Not yet recruiting NCT05381415 - Effect on Bronchodilation Response and Ventilation Heterogeneity of Different Inhalation Volumes in COPD
Recruiting NCT04989439 - Comparison of Computertomography Scan, Electrical Impedance Tomography, and Ultrasound of the Lung in Infants
Not yet recruiting NCT06133777 - Respiratory Variability and Postoperative Complications During Thoracic Lung Resection. N/A